Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Different Forms of TAK-994 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-994

First Posted Date: 2021-02-09

Last Posted Date: 2021-04-22

Lead Sponsor: Takeda

Target Recruit Count: 54

Registration Number: NCT04745767

Locations: 🇺🇸
Celerion Lincoln, NE site, Lincoln, Nebraska, United States
🇺🇸
Celerion Tempe, AZ site, Tempe, Arizona, United States

A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Phase 3

Recruiting

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Vedolizumab

First Posted Date: 2021-02-04

Last Posted Date: 2024-12-27

Lead Sponsor: Takeda

Target Recruit Count: 158

Registration Number: NCT04738942

Locations: 🇯🇵
Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵
Ieda Hospital, Toyota, Aichi, Japan
🇯🇵
Hirosaki University Hospital, Hirosaki, Aomori, Japan

and more 17 locations

A Study of TAK-510 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-510
Drug: TAK-510 Placebo

First Posted Date: 2021-02-01

Last Posted Date: 2024-03-04

Lead Sponsor: Takeda

Target Recruit Count: 124

Registration Number: NCT04731922

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Phase 4

Completed

Conditions: Gaucher Disease

Interventions: Other: Digital Engagement Application (GD App)
Other: No Intervention

First Posted Date: 2021-01-22

Last Posted Date: 2023-12-21

Lead Sponsor: Takeda

Target Recruit Count: 4

Registration Number: NCT04718779

Locations: 🇺🇸
The Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States

A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

Completed

Conditions: Gaucher Disease

Interventions: Other: Standard of Care

First Posted Date: 2021-01-22

Last Posted Date: 2024-03-29

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT04721366

Locations: 🇺🇸
Lysosomal & Rare Disorders Research & Treatment Center, Fairfax, Virginia, United States

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Phase 1

Completed

Conditions: Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Interventions: Biological: TAK-019
Biological: Placebo

First Posted Date: 2021-01-15

Last Posted Date: 2023-06-06

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT04712110

Locations: 🇯🇵
Nishi Kumamoto Hospital, Kumamoto, Japan
🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan

A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

Phase 3

Recruiting

Conditions: Crohn's Disease
Complex Perianal Fistula

Interventions: Biological: Darvadstrocel

First Posted Date: 2021-01-08

Last Posted Date: 2024-02-20

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT04701411

Locations: 🇳🇱
Erasmus Medisch Centrum, Rotterdam, Netherlands
🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
🇪🇸
Hospital Sant Joan de Deu, Barcelona, Spain

and more 19 locations

Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

Phase 3

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: TAK-743 300 mg

First Posted Date: 2020-12-29

Last Posted Date: 2023-06-26

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT04687137

Locations: 🇯🇵
Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan
🇯🇵
Kobe University Hospital, Kobe, Hyogo, Japan
🇯🇵
Tokai University Hospital, Isehara, Kanagawa, Japan

and more 6 locations

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Phase 3

Recruiting

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)

Interventions: Biological: TAK-755

First Posted Date: 2020-12-24

Last Posted Date: 2024-04-29

Lead Sponsor: Takeda

Target Recruit Count: 77

Registration Number: NCT04683003

Locations: 🇺🇸
University of Minnesota Health Clinical Research Unit, Minneapolis, Minnesota, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Mid Ohio Heart Clinic Inc, Dublin, Ohio, United States

and more 26 locations

A Study of TAK-919 in Healthy Japanese Adults (COVID-19)

Phase 1

Completed

Conditions: Coronavirus Disease (COVID-19)

Interventions: Biological: TAK-919
Biological: Placebo

First Posted Date: 2020-12-21

Last Posted Date: 2023-05-03

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT04677660

Locations: 🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵
PS Clinic, Fukuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy